Bone methabolic disorders in HIV positive patients: a case report
- PMID: 32921777
- PMCID: PMC7716982
- DOI: 10.23750/abm.v91i3.9026
Bone methabolic disorders in HIV positive patients: a case report
Abstract
Fractures in patients affected by HIV are more frequent than what is reported in patients with no retroviral diseases. Chronic infection with HIV likely contributes to increased systemic inflammation, which has been associated with increased rates of fracture. We report a case of a 56-year-old male (HIV + in treatment with Atripla) heavy worker, at the beginning affected by intra-articular proximal humerus fracture treated with endoprosthesis replacement and later by periprosthetic fracture treated with plate, screws and cerclages. Follow up was performed with clinical evaluation (ROM, VAS, Quick Dash, ASES, Simple shoulder test, UCLA Score, Constant score) and shoulder radiographs. Bone metabolism disorders in HIV patients lead to low BMD values, changes in bone turnover markers, and histomorphometric abnormalities, especially when HIV is present along with HCV or other hepatopathies. Additional therapy with bisphosphonate and Vitamin D should always be carried out when possible to prevent such types of orthopaedic complications.
Conflict of interest statement
Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article
Figures
References
-
- Battalora L, Buchacz K, Armon C, et al. Low bone mineral density and risk of incident fracture in HIV-infected adults. Antivir Ther. 2016;21:45–54. - PubMed
-
- Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virusinfected individuals. Clin Infect Dis. 2003;36:482–90. - PubMed
-
- Cassetti I, Madruga JV, Suleiman JM, et al. Study 903E Team*. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviralnaıve HIV-1-infected patients. HIV Clin Trials. 2007;8:164–72. - PubMed
-
- Assoumou L, Katlama C, Viard JP, et al. ANRS Osteovir study group. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27:2425–30. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Medical